Innovating Works

IseeG

Financiado
FunctIonal optoacousticS for imaging Early onsEt of Gut inflammation
"The aim of this project is to functionalize contrast agents for multispectral optoacoustic tomography (MSOT) - a molecular ""sensitive"" ultrasound imaging technique - to develop a new targeted imaging approach for the early loca... "The aim of this project is to functionalize contrast agents for multispectral optoacoustic tomography (MSOT) - a molecular ""sensitive"" ultrasound imaging technique - to develop a new targeted imaging approach for the early localisation of inflammatory processes. Inflammatory processes in the gastrointestinal tract often act like a Trojan horse - while camouflaging themselves with diffuse clinical symptoms, they may rapidly progress into life-threatening complications. To date, it has been difficult to precisely localize them in their early stages, and their detection remains the domain of invasive endoscopy. The invasive nature of this method not only restricts its use for early disease detection, but is a major limitation for repetitive or high-risk applications. MSOT uses laser light excitation and ultrasound detection to resolve different chromophores such as haemoglobin, lipids, and other metabolic parameters at depths of several centimetres. While we were using the response from endogenous chromophores for translational to a range of potential clinical applications, we discovered that dyes delivered via the oral route enable the dynamic visualization of the entire intestinal tract. This molecular-sensitive approach has the advantage that such contrast agents are not absorbed systemically and undergo excretion largely unchanged. Based on this, I hypothesize that it is possible to functionalize such contrast agents in order to put a molecular flag on inflamed areas in the gastrointestinal tract. After characterizing potential imaging targets in the intestinal lumen and developing imaging agents, we will take a translational research approach, moving from cells through small and large experimental animal models back to the human system. This research at the frontiers of medicine and physics may pave the way to non-invasive early detection and personalized treatment strategies while minimizing the procedural risk for affected patients." ver más
30/11/2028
1M€
Duración del proyecto: 60 meses Fecha Inicio: 2023-11-20
Fecha Fin: 2028-11-30

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-20
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2023-STG: ERC STARTING GRANTS
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 1M€
Líder del proyecto
UNIVERSITATSKLINIKUM ERLANGEN No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5